Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (T³)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
French Innovative Leukemia Organisation
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier:
NCT01389427
First received: July 4, 2011
Last updated: April 13, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2016
  Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)